Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 11, 2003. The report details specific corporate actions regarding share re-purchases and updates on directors' interests in company shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only specific financial data disclosed relates to share transactions:
- Share Re-purchase: 950,000 ordinary shares purchased for cancellation at 1052.3275p per share.
- US Retirement Savings Plan: Fund holdings decreased from 18,596,424 to 18,507,017 Ordinary Share ADRs at an average price of $34.19.
- Employee Trust Transactions: 4,119 ordinary shares sold at £10.60 per share; 6,154 ordinary shares transferred to a Long Term Incentive Plan participant.
Material Changes
The filing reports a reduction in the company's outstanding share count due to the cancellation of 950,000 shares. Additionally, there were minor adjustments in the number of shares held by the US Retirement Savings Plan and the GlaxoSmithKline Employee Trust.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is strictly a notification of recent share transactions and changes in director interests.
Key Facts for Investor Verification
- Verify the total number of shares repurchased and cancelled against the authority granted at the May 20, 2002 Annual General Meeting.
- Confirm the impact of the 950,000 share cancellation on the company's total share capital.
- Review the specific director interests disclosed (Dr. J P Garnier and Mr. J D Coombe) regarding the Employee Trust and US Retirement Plan.
- Note that this filing does not contain quarterly or annual financial performance data.